This prospective study assessed the quality of life of patients with transfusion-dependent betathalassemia receiving three different iron chelation treatments. Patients enrolled were receiving one of the following chelation therapies: Group-I: deferoxamine (n=21), Group-II: deferasirox (n=75) and Group-III: deferoxamine in combination with deferiprone (n=39).
Introduction
Beta-thalassemia is a genetically inherited disorder characterized by reduced synthesis of the betahemoglobin chain which in turn results in reduced synthesis of hemoglobin A (HbA). To date more than 1,000 mutations are known that influence the structure or synthesis of the alpha-and beta-globin chains that make up HbA and which are listed in the HbVar database (HbVar), a database of all the mutations related to thalassemia and the variations of hemoglobin 1, 2, 3 . Treatment of patients with thalassemia major consists of regular blood transfusions and iron chelation therapy, which is vital to prevent excess iron buildup in the body. In Bangladesh there are three iron chelating agents available: deferoxamine (DFO, Desferal), an iron chelator given by infusion, and two oral chelators deferiprone (DFP, Ferriprox) and deferasirox (DFX, Exjade). Treatment with iron chelators has significantly increased the life expectancy of affected individuals into the third to fifth decade 4 , while simultaneously decreasing the comorbidities of the disease 5 .
Despite advancements in care, patients with transfusion-dependent beta-thalassemia still present complications and often suffer from psychological problems due to their lifestyle 6 . While the effectiveness of iron chelation therapies has been thoroughly investigated, there is limited comparative information about the benefits of the therapies on the quality of life and self-esteem of the patients. Furthermore, the quality of life of patients presenting with this disease and the effect of the type of iron chelation treatment on the patient's quality of life have not been evaluated. Thus, the objective of the present study was to compare the quality of life, self-esteem, and satisfaction and adherence to treatment of patients with transfusion-dependent beta-thalassemia in Bangladeshi population receiving three different chelation treatments and to identify parameters affecting their quality of life. The SF-36 questionnaire was used in order to evaluate the quality of life in the 135 patients of the study. Three other questionnaires were administered which provided important information on factors varying among patients receiving different types of iron chelation therapy.
Methods

Patients:
A total of 135 transfusion-dependent beta-thalassemia Patients attending in the Bangladesh Thalassemia Centre and Haematology department of BSMMU (Bangabandhu Sheikh Mujib Medical University) Dhaka between February 2012 and February 2013 were enrolled in the study. During this time period, 174 betathalassemia patients were attending the aforementioned two-three units; 39 did not return their questionnaires and did not provide reasons for dropping out of the study. Diagnosis with transfusion-dependent beta-thalassemia was the only criterion used for inclusion in the study. There were no exclusion criteria. The scientific committee of the study and the local ethics committees of the participating hospitals approved the study. All patients provided written informed consent for their participation.
Evaluation Questionnaires: All patients were asked to answer the following four questionnaires: (i) the SF-36 questionnaire [10] ; (ii) a Wallston's health locus of control scale, in which the patients answered 18 questions using a 6-point Likert-type scale response format [11] with 1 and 2 = strongly and moderately disagree, respectively, 3 = neither agree nor disagree, and 4, 5, and 6 = slightly, moderately, and strongly agree, respectively; (iii) a self-esteem questionnaire with 13 questions using a 5-point Likert-type scale (with 1 = very well and 5 = very poorly); (iv) a questionnaire about patient satisfaction from their current therapeutic chelator with 41 questions with responses varying from never to always. In addition, personal data and the hematological profile of the patients were obtained in order to be able to better evaluate the quality of life of the patients enrolled in our study.
Statistical Analysis: All continuous variables are expressed as the mean ± standard deviation (SD). The categorical (nominal) variables are expressed as percentages of the total population. Comparisons of the categorical variables between the three therapies were performed by the chi square test. Differences were considered significant when the P value was <0.05.
In order to investigate if chelation treatment is associated with patients' quality of life, univariate regression analysis was performed in which the eight scales and the two components of the SF-36 were set as dependent variables and chelation treatment was set as the independent variable.
Statistical analyses were performed with SPSS version 18.0 for Windows 7.
Results
Patient Characteristics:
Of the 135 adult patients with transfusion-dependent beta-thalassemia that were recruited in this study, 59 were males and 76 were females. The patients were divided into three groups based on the therapy they were receiving: the first group was receiving deferoxamine (DFO; Desferal, Novartis), the second group deferasirox (DFX; Exjade, Novartis), and the third group deferoxamine + deferiprone (DFP; Ferriprox, Demo S.A.) combination therapy.
The mean age of the patients was 37.3±10.1 for the DFO group, 34.3±7.4 for the DFX group, and 37.8±8.3 for the DFO + DFP group. The differences among the groups were not statistically significant. The demographic characteristics of the patients are shown in Table 1 
NS
Disease
Characteristics:
The disease characteristics of patients of the three groups are presented in Table 2 . There were no significant differences among the three groups between their age at the time of diagnosis and their age when DFO treatment began. When examining the comorbidities, the patients receiving DFO had significantly higher percentages of myocardial dysfunction (33.3%) and hepatic dysfunction (38.1%), while 71.4% had undergone splenectomy and 14.3% suffered from allergies (Table 3) 
Results from Questionnaires:
The SF-36 questionnaire was used as a measurement of the quality of life of the patients. This questionnaire consists of eight scales (1) physical functioning, (2) role limitations because of physical health problems, (3) bodily pain, (4) general health perceptions, (5) vitality (energy/fatigue), (6) social functioning, (7) role limitations due to emotional problems, and (8) general mental health (psychological distress and psychological wellbeing). The scores were calculated for respondents completing 50% or more of the items within a scale. Higher scores represent better health. The type of chelation treatment was proven to be statistically significantly associated with physical functioning (P=0.048), role limitations due to physical health problems (P=0.021), bodily pain (P=0.015), vitality (P<0.001), and mental health (P=0.001) ( Table 4) . Pairwise comparisons performed in the aforementioned scales in order to ascertain differences among the treatments revealed that those who received DFX or DFO + DFP demonstrated significantly higher mean scores (better quality of life) than patients who received DFO alone, in all scales tested, apart from the bodily pain scale. In the bodily pain scale, only treatment with DFX resulted in a significantly higher mean score than treatment with DFO alone Association between SF-36 scales and chelation treatment Univariate analysis; NS: not significant, value< 0.05 indicated statistical differences among the three groups.
Discussion
One hundred and thirty-five adult beta-thalassemia transfusion-dependent patients took part in this study. The majority of the patients were single without children, in agreement with previous reports 9 . One-fifth of the patients were unemployed, a not very high percentage.
The DFO + DFP combination therapy offers a better control of serum ferritin levels, thus requiring less frequent DFO infusions 10 . It was thus not surprising that we found a decreased frequency of transfusions in the DFO + DFP combination group (P<0.0001; Table 2 ). A higher percentage of DFO patients had comorbidities compared to the other two groups, except for thyroid disease, which was more prevalent in DFX patients. The presence of hepatic dysfunction in patients with homozygous beta-thalassemia has been correlated with iron overload in the liver as well as to chronic hepatitis 11 . It is also notable that patients receiving DFX had the lowest prevalence of myocardiopathy which is in accordance with reports on the ability of DFX to prevent iron overload in the myocardium 12 .
The highest rate of patient adherence to treatment was observed in the DFX patients. Adherence to therapy is the most important parameter for successful therapy. In fact low adherence of patients receiving DFO has been linked to the absence of clinical benefit 5 . In a previous study, low adherence to DFO was linked to smoking and to difficulties with self-administering the infusion 13 .
Our results about satisfaction and ease of receiving their therapy matched those of previous studies, in which DFX was associated with increased satisfaction to treatment. Importantly, it was shown that switching chelators resulted in increased adherence, regardless of whether the patients switched from the oral to the intravenous chelator or vice versa, although the switch from DFO to DFP occurred more often 14 .
According to previous studies, patients receiving DFO were more likely to suffer from depression, fatigue, dyspnea, and decreased physical functioning 15 . The majority of patients felt that they could participate in more activities if they were not receiving DFO 16 in accordance with the results of our study indicating that DFO limited the ability of patients to participate in sports and perform daily functions. Furthermore, the results of our study indicate that patients receiving DFO had lower self-esteem and worse PCS scores. These observations are in agreement with the results of the ITHACA study, in which the PCS score was low for patients receiving DFO 17 and with the study of Abetz et al., in which patients with DFO suffered from low self-esteem 15 .
Of the specific components of the SF-36 questionnaire, the type of chelation treatment was proven to be statistically significantly associated with physical functioning, role limitations due to physical health problems, bodily pain, vitality, and mental health. Importantly, the results of our multivariate analysis indicate that the dependence of the PCS score on the type of chelation treatment was not confounded by anthropometric variables, such as gender, marital status, level of physical activity, presence of comorbidities, or smoking status. The importance of the SF-36 questionnaire and the results of the individual scales on the multidisciplinary actions that should be taken for patients with beta-thalassemia have been reported 18 .
The study is not without limitations. A randomized controlled clinical trial would be needed to ascertain the cause and effect relationship between quality of life and type of iron chelation therapy. Future studies should be of this design. However, its design as a prospective study of patients attending the pediatric, medicine and hematology units of the Rajshahi Medical College Hospital, Pabna Medical College Hospital and Bangladesh Thalassemia Centre is ideal for reflecting daily clinical practice and the impact on the quality of life of these patients in "real-life."
Conclusions
In conclusion, our study provides support for differences in the limitations of daily activities, physical activity, and quality of life among patients with transfusion-dependent betathalassemia depending on the type of their chelation therapy. Furthermore, the adherence to treatment, the ease and satisfaction from their therapy, and patient self-esteem differed along the three groups. This study highlights the importance of providing beta-thalassemia patients with the optimal chelation treatment based on their individual needs, in order to decrease the presence of unwanted comorbidities and to increase the quality of life, leading to increased adherence and thus resulting in optimal clinical benefit.
Recommendations
Furthermore, our results highlight the need of the involvement of a multidisciplinary team in the management of patients with this disease.
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